Core Viewpoint - The stock of Innovent Biologics-B (02591) rose over 3%, reaching HKD 32, following the announcement that its innovative drug, Icosapent Ethyl (brand name: Yinuo Qing®), has been included in the 2025 National Medical Insurance Drug List in China, marking a significant step towards making diabetes treatment more accessible [1]. Group 1: Company Developments - Innovent Biologics' Icosapent Ethyl is the first long-acting human GLP-1 receptor agonist (GLP-1RA) developed in China, aimed at controlling blood sugar levels in adult patients with type 2 diabetes [1]. - The drug will officially be implemented in the national insurance scheme starting January 1, 2026, enhancing its market accessibility [1]. Group 2: Industry Impact - The inclusion of Icosapent Ethyl in the national insurance list aligns with the "Healthy China 2030" initiative, which aims to advance diabetes prevention and treatment [1]. - The National Guidelines for Diabetes Prevention and Management (2025) classify Icosapent Ethyl as a GLP-1RA injectable medication, providing a policy framework for its use in primary healthcare settings [1]. - The guidelines highlight GLP-1RA as a crucial treatment option for adult type 2 diabetes patients with comorbidities such as atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), and those needing weight management [1].

Core Viewpoint - The stock of Sino Biopharmaceutical-B (02591) has experienced a significant decline of over 25% following its inclusion in the Hong Kong Stock Connect, with a current trading price of HKD 32.9 and a trading volume of HKD 19.69 million [1] Group 1: Stock Performance - Sino Biopharmaceutical-B's stock fell more than 14% after being included in the Hong Kong Stock Connect and has continued to decline, with a total drop of 25% [1] - As of the latest update, the stock is down 12.73% at HKD 32.9, with a trading volume of HKD 19.69 million [1] Group 2: Regulatory Changes - The Shanghai and Shenzhen Stock Exchanges announced adjustments to the constituent stocks of the Hang Seng Composite MidCap Index, resulting in the inclusion of Sino Biopharmaceutical in the Hong Kong Stock Connect, effective from December 8, 2025 [1] Group 3: Product Development - Sino Biopharmaceutical announced that its self-developed long-acting GLP-1 receptor agonist, Ispaglutide α (Yinuo Qing®), has been officially included in the National Medical Insurance Drug List for 2025, set to take effect on January 1, 2026 [1] - Ispaglutide α (Yinuo Qing®) is recognized as a domestically produced long-acting GLP-1 receptor agonist [1]

Group 1 - The core viewpoint of the article highlights that SINO PHARMACEUTICAL (02591) experienced a significant decline of over 13% after a two-week cumulative increase of 50% in its stock price [1] - As of the report, the stock price dropped by 13.64%, trading at 38 HKD with a transaction volume of 30.31 million HKD [1] - The Shanghai and Shenzhen Stock Exchanges announced that SINO PHARMACEUTICAL will be included in the Hong Kong Stock Connect effective from December 8, 2025, due to adjustments in the Hang Seng Composite MidCap Index [1] Group 2 - SINO PHARMACEUTICAL's self-developed long-acting GLP-1 receptor agonist, Ispaglutide α (Yinuo Qing®), has been officially included in the National Medical Insurance Drug List for 2025, set to be implemented alongside the new list on January 1, 2026 [1]

Core Viewpoint - Silver诺医药-B (02591) experienced a decline of over 13% after a significant increase of 50% in the previous two weeks [1] Group 1: Stock Performance - As of the report, the stock price dropped by 13.64%, trading at 38 HKD with a transaction volume of 30.31 million HKD [1] Group 2: Regulatory Changes - The Shanghai and Shenzhen Stock Exchanges announced adjustments to the Hang Seng Composite MidCap Index, resulting in Silver诺医药 being included in the Hong Kong Stock Connect list, effective from December 8, 2025 [1] Group 3: Product Development - Silver诺医药's self-developed long-acting GLP-1 receptor agonist, Eysuparaglutide α (怡诺轻®), has been officially included in the National Medical Insurance Drug List for 2025, set to be implemented alongside the new list starting January 1, 2026 [1]